News|Articles|September 30, 2024
Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer
Author(s)Gina Mauro
Fact checked by: Ariana Pelosci
Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.
Advertisement
Advertisement
The standard schedule of 70 Gy intensity-modulated radiation therapy (IMRT) plus cisplatin was not inferior to a deintensification Gy IMRT schedule or to a regimen using nivolumab (Opdivo) vs cisplatin in patients with p16-positive oropharyngeal cancer, according to results of a futility analysis of the phase 2/3 NRG-HN005 trial (NCT03952585) that was presented at the
Advertisement
Advertisement